The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
Almost all drugs approved for use in humans possess potentially beneficial off-target' effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing F...
| Main Authors: | , , , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Wiley
2015
|
| 主题: | |
| 在线阅读: | http://eprints.um.edu.my/14906/1/Patmanathan_et_al-2015-Journal_of_Cellular_and_Molecular_Medicine.pdf |
| _version_ | 1825720601327697920 |
|---|---|
| author | Patmanathan, S.N. Yap, L.F. Murray, P.G. Paterson, I.C. |
| author_facet | Patmanathan, S.N. Yap, L.F. Murray, P.G. Paterson, I.C. |
| author_sort | Patmanathan, S.N. |
| collection | UM |
| description | Almost all drugs approved for use in humans possess potentially beneficial off-target' effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing FTY720 (also known as fingolimod, Gilenya), an immunomodulatory drug recently approved for the treatment of multiple sclerosis (MS). The therapeutic benefit of FTY720 in MS is largely attributed to the immunosuppressive effects that result from its modulation of sphingosine 1-phosphate receptor signalling. However, this drug has also been shown to inhibit other cancer-associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti-cancer agent both invitro and invivo. Here, we review the effects of FTY720 on signal transduction pathways and cancer-related cellular processes, and discuss its potential use as an anti-cancer drug.
|
| first_indexed | 2024-03-06T05:37:35Z |
| format | Article |
| id | um.eprints-14906 |
| institution | Universiti Malaya |
| language | English |
| last_indexed | 2025-03-05T02:47:26Z |
| publishDate | 2015 |
| publisher | Wiley |
| record_format | dspace |
| spelling | um.eprints-149062024-10-14T07:53:32Z http://eprints.um.edu.my/14906/ The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod Patmanathan, S.N. Yap, L.F. Murray, P.G. Paterson, I.C. RK Dentistry Almost all drugs approved for use in humans possess potentially beneficial off-target' effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing FTY720 (also known as fingolimod, Gilenya), an immunomodulatory drug recently approved for the treatment of multiple sclerosis (MS). The therapeutic benefit of FTY720 in MS is largely attributed to the immunosuppressive effects that result from its modulation of sphingosine 1-phosphate receptor signalling. However, this drug has also been shown to inhibit other cancer-associated signal transduction pathways in part because of its structural similarity to sphingosine, and consequently shows efficacy as an anti-cancer agent both invitro and invivo. Here, we review the effects of FTY720 on signal transduction pathways and cancer-related cellular processes, and discuss its potential use as an anti-cancer drug. Wiley 2015 Article PeerReviewed application/pdf en http://eprints.um.edu.my/14906/1/Patmanathan_et_al-2015-Journal_of_Cellular_and_Molecular_Medicine.pdf Patmanathan, S.N. and Yap, L.F. and Murray, P.G. and Paterson, I.C. (2015) The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod. Journal of Cellular and Molecular Medicine, 19 (10). ISSN 1582-1838, DOI https://doi.org/10.1111/jcmm.12635 <https://doi.org/10.1111/jcmm.12635>. http://onlinelibrary.wiley.com/doi/10.1111/jcmm.12635/abstract 10.1111/jcmm.12635 |
| spellingShingle | RK Dentistry Patmanathan, S.N. Yap, L.F. Murray, P.G. Paterson, I.C. The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod |
| title | The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
|
| title_full | The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
|
| title_fullStr | The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
|
| title_full_unstemmed | The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
|
| title_short | The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
|
| title_sort | antineoplastic properties of fty720 evidence for the repurposing of fingolimod |
| topic | RK Dentistry |
| url | http://eprints.um.edu.my/14906/1/Patmanathan_et_al-2015-Journal_of_Cellular_and_Molecular_Medicine.pdf |
| work_keys_str_mv | AT patmanathansn theantineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT yaplf theantineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT murraypg theantineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT patersonic theantineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT patmanathansn antineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT yaplf antineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT murraypg antineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod AT patersonic antineoplasticpropertiesoffty720evidencefortherepurposingoffingolimod |